Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.71 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | IL1B | P01584 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26258573 | 0.92 | CRBN (0.69) | CRBNDDB1IKZF1CSNK1A1HDAC1 | |
| SCHEMBL1962176 | 0.89 | CRBN (0.76) | CRBNDDB1IKZF1CSNK1A1HDAC1 | |
| SCHEMBL2383195 | 0.89 | CRBN (0.78) | CRBNDDB1IKZF1CSNK1A1HDAC1 | |
| SCHEMBL26258568 | 0.88 | CRBN (0.73) | CRBNDDB1IKZF1CSNK1A1HDAC1 | |
| SCHEMBL1962472 | 0.88 | CRBN (0.70) | CRBNDDB1IKZF1CSNK1A1HDAC1 | |
| SCHEMBL2382779 | 0.88 | CRBN (0.73) | CRBNDDB1IKZF1CSNK1A1HDAC1 | |
| SCHEMBL1961981 | 0.88 | CRBN (0.73) | CRBNDDB1IKZF1CSNK1A1HDAC1 | |
| SCHEMBL1962651 | 0.88 | CRBN (0.73) | CRBNDDB1IKZF1CSNK1A1HDAC1 | |
| SCHEMBL1964798 | 0.87 | CRBN (0.72) | CRBNDDB1IKZF1CSNK1A1HDAC1 | |
| SCHEMBL14606853 | 0.87 | CRBN (0.72) | CRBNDDB1IKZF1CSNK1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | CRBN 21/4885DDB1 550/4885IKZF1 865/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | CRBN 46/4885DDB1 762/4885IKZF1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.